S&P 500   3,852.73 (-0.07%)
DOW   30,982.98 (+0.07%)
QQQ   328.69 (+0.18%)
AAPL   142.26 (-0.46%)
MSFT   232.71 (+1.39%)
FB   282.28 (+1.54%)
GOOGL   1,903.36 (+0.48%)
AMZN   3,321.01 (+0.82%)
TSLA   887.11 (+0.72%)
NVDA   540.18 (-1.09%)
BABA   262.77 (+0.53%)
CGC   35.07 (+6.56%)
GE   11.23 (+2.18%)
MU   80.50 (-0.96%)
AMD   95.06 (+0.99%)
NIO   59.68 (-0.52%)
T   29.35 (+0.82%)
F   11.14 (-1.33%)
ACB   10.57 (+4.04%)
BA   202.07 (-0.63%)
DIS   170.75 (-0.66%)
NFLX   567.21 (+1.87%)
GILD   66.81 (-1.98%)
S&P 500   3,852.73 (-0.07%)
DOW   30,982.98 (+0.07%)
QQQ   328.69 (+0.18%)
AAPL   142.26 (-0.46%)
MSFT   232.71 (+1.39%)
FB   282.28 (+1.54%)
GOOGL   1,903.36 (+0.48%)
AMZN   3,321.01 (+0.82%)
TSLA   887.11 (+0.72%)
NVDA   540.18 (-1.09%)
BABA   262.77 (+0.53%)
CGC   35.07 (+6.56%)
GE   11.23 (+2.18%)
MU   80.50 (-0.96%)
AMD   95.06 (+0.99%)
NIO   59.68 (-0.52%)
T   29.35 (+0.82%)
F   11.14 (-1.33%)
ACB   10.57 (+4.04%)
BA   202.07 (-0.63%)
DIS   170.75 (-0.66%)
NFLX   567.21 (+1.87%)
GILD   66.81 (-1.98%)
S&P 500   3,852.73 (-0.07%)
DOW   30,982.98 (+0.07%)
QQQ   328.69 (+0.18%)
AAPL   142.26 (-0.46%)
MSFT   232.71 (+1.39%)
FB   282.28 (+1.54%)
GOOGL   1,903.36 (+0.48%)
AMZN   3,321.01 (+0.82%)
TSLA   887.11 (+0.72%)
NVDA   540.18 (-1.09%)
BABA   262.77 (+0.53%)
CGC   35.07 (+6.56%)
GE   11.23 (+2.18%)
MU   80.50 (-0.96%)
AMD   95.06 (+0.99%)
NIO   59.68 (-0.52%)
T   29.35 (+0.82%)
F   11.14 (-1.33%)
ACB   10.57 (+4.04%)
BA   202.07 (-0.63%)
DIS   170.75 (-0.66%)
NFLX   567.21 (+1.87%)
GILD   66.81 (-1.98%)
S&P 500   3,852.73 (-0.07%)
DOW   30,982.98 (+0.07%)
QQQ   328.69 (+0.18%)
AAPL   142.26 (-0.46%)
MSFT   232.71 (+1.39%)
FB   282.28 (+1.54%)
GOOGL   1,903.36 (+0.48%)
AMZN   3,321.01 (+0.82%)
TSLA   887.11 (+0.72%)
NVDA   540.18 (-1.09%)
BABA   262.77 (+0.53%)
CGC   35.07 (+6.56%)
GE   11.23 (+2.18%)
MU   80.50 (-0.96%)
AMD   95.06 (+0.99%)
NIO   59.68 (-0.52%)
T   29.35 (+0.82%)
F   11.14 (-1.33%)
ACB   10.57 (+4.04%)
BA   202.07 (-0.63%)
DIS   170.75 (-0.66%)
NFLX   567.21 (+1.87%)
GILD   66.81 (-1.98%)
Log in
NASDAQ:MASI

Masimo Competitors

$252.07
-5.02 (-1.95 %)
(As of 01/26/2021 12:15 PM ET)
Add
Compare
Today's Range
$250.96
Now: $252.07
$258.43
50-Day Range
$261.00
MA: $268.07
$283.75
52-Week Range
$143.90
Now: $252.07
$284.86
Volume5,947 shs
Average Volume280,917 shs
Market Capitalization$13.88 billion
P/E Ratio65.47
Dividend YieldN/A
Beta0.87

Competitors

Masimo (NASDAQ:MASI) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying MASI stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Masimo, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Masimo (NASDAQ:MASI) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Masimo and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Abbott Laboratories121302.75

Masimo presently has a consensus target price of $261.1667, suggesting a potential upside of 3.59%. Abbott Laboratories has a consensus target price of $115.6875, suggesting a potential upside of 0.99%. Given Masimo's higher possible upside, equities research analysts clearly believe Masimo is more favorable than Abbott Laboratories.

Valuation and Earnings

This table compares Masimo and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.80$196.22 million$3.2278.28
Abbott Laboratories$31.90 billion6.35$3.69 billion$3.2435.28

Abbott Laboratories has higher revenue and earnings than Masimo. Abbott Laboratories is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Masimo and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Abbott Laboratories10.50%18.19%8.29%

Risk & Volatility

Masimo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Institutional & Insider Ownership

81.6% of Masimo shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 11.5% of Masimo shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Masimo beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Institutional & Insider Ownership

81.6% of Masimo shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 11.5% of Masimo shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Masimo and Medtronic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Medtronic032012.92

Masimo presently has a consensus target price of $261.1667, suggesting a potential upside of 3.59%. Medtronic has a consensus target price of $122.2963, suggesting a potential upside of 4.31%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Masimo.

Valuation and Earnings

This table compares Masimo and Medtronic's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.80$196.22 million$3.2278.28
Medtronic$28.91 billion5.45$4.79 billion$4.5925.49

Medtronic has higher revenue and earnings than Masimo. Medtronic is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Masimo and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Medtronic12.69%9.71%5.30%

Summary

Masimo beats Medtronic on 8 of the 15 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 71.5% of Stryker shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Masimo and Stryker, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Stryker271412.58

Masimo presently has a consensus price target of $261.1667, suggesting a potential upside of 3.59%. Stryker has a consensus price target of $227.4783, suggesting a potential downside of 5.03%. Given Masimo's stronger consensus rating and higher probable upside, analysts plainly believe Masimo is more favorable than Stryker.

Earnings & Valuation

This table compares Masimo and Stryker's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.80$196.22 million$3.2278.28
Stryker$14.88 billion6.04$2.08 billion$8.2628.94

Stryker has higher revenue and earnings than Masimo. Stryker is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Profitability

This table compares Masimo and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Stryker12.35%20.94%8.77%

Summary

Masimo beats Stryker on 8 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Masimo and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Intuitive Surgical381002.33

Masimo presently has a consensus price target of $261.1667, suggesting a potential upside of 3.59%. Intuitive Surgical has a consensus price target of $736.0588, suggesting a potential downside of 3.53%. Given Masimo's stronger consensus rating and higher probable upside, analysts plainly believe Masimo is more favorable than Intuitive Surgical.

Earnings & Valuation

This table compares Masimo and Intuitive Surgical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.80$196.22 million$3.2278.28
Intuitive Surgical$4.48 billion20.14$1.38 billion$9.9577.13

Intuitive Surgical has higher revenue and earnings than Masimo. Intuitive Surgical is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Masimo and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Intuitive Surgical24.45%12.08%10.44%

Summary

Intuitive Surgical beats Masimo on 9 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 83.2% of Becton, Dickinson and shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Masimo and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Becton, Dickinson and07702.50

Masimo presently has a consensus price target of $261.1667, suggesting a potential upside of 3.59%. Becton, Dickinson and has a consensus price target of $279.6667, suggesting a potential upside of 9.11%. Given Becton, Dickinson and's higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than Masimo.

Earnings & Valuation

This table compares Masimo and Becton, Dickinson and's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.80$196.22 million$3.2278.28
Becton, Dickinson and$17.12 billion4.37$874 million$10.2025.23

Becton, Dickinson and has higher revenue and earnings than Masimo. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Masimo and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Becton, Dickinson and5.11%13.30%5.60%

Masimo (NASDAQ:MASI) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Masimo and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Edwards Lifesciences271202.48

Masimo presently has a consensus price target of $261.1667, suggesting a potential upside of 3.59%. Edwards Lifesciences has a consensus price target of $90.8704, suggesting a potential upside of 5.60%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Masimo.

Earnings & Valuation

This table compares Masimo and Edwards Lifesciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.80$196.22 million$3.2278.28
Edwards Lifesciences$4.35 billion12.46$1.05 billion$1.8646.75

Edwards Lifesciences has higher revenue and earnings than Masimo. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Masimo and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Edwards Lifesciences18.18%29.00%18.10%

Summary

Edwards Lifesciences beats Masimo on 8 of the 14 factors compared between the two stocks.


Masimo Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$114.32-0.3%$203.33 billion$31.90 billion60.49Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$117.01-0.1%$157.35 billion$28.91 billion44.66
Stryker logo
SYK
Stryker
2.0$239.07-0.2%$90.02 billion$14.88 billion51.86Upcoming Earnings
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$767.43-2.0%$88.40 billion$4.48 billion87.41Earnings Announcement
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$257.32-1.1%$75.69 billion$17.12 billion94.26Dividend Announcement
News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$86.95-1.2%$53.53 billion$4.35 billion69.56Upcoming Earnings
Boston Scientific logo
BSX
Boston Scientific
2.2$36.62-0.4%$52.67 billion$10.74 billion14.03
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$482.76-1.3%$41.73 billion$2.41 billion84.10Upcoming Earnings
Baxter International logo
BAX
Baxter International
2.3$79.96-0.2%$40.92 billion$11.36 billion45.43
DexCom logo
DXCM
DexCom
1.9$364.56-3.2%$36.14 billion$1.48 billion150.64Insider Selling
ResMed logo
RMD
ResMed
1.4$221.62-0.0%$32.12 billion$2.96 billion47.56Upcoming Earnings
Hologic logo
HOLX
Hologic
1.9$74.95-1.9%$19.62 billion$3.78 billion17.85Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$281.25-2.7%$19.05 billion$738.20 million639.22
Teleflex logo
TFX
Teleflex
2.0$379.91-0.6%$17.80 billion$2.60 billion48.89
STERIS logo
STE
STERIS
2.1$192.60-1.1%$16.25 billion$3.03 billion39.07Upcoming Earnings
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.15-0.1%$16.02 billion$3.17 billion59.78News Coverage
Abiomed logo
ABMD
Abiomed
1.5$343.17-1.5%$15.74 billion$840.88 million75.42Upcoming Earnings
Hill-Rom logo
HRC
Hill-Rom
2.0$100.30-0.9%$6.71 billion$2.88 billion30.21
Globus Medical logo
GMED
Globus Medical
1.4$64.02-0.7%$6.36 billion$785.37 million69.59
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.73-0.5%$5.85 billion$1.52 billion104.07
NuVasive logo
NUVA
NuVasive
1.5$58.15-2.3%$2.91 billion$1.17 billion-264.32
AtriCure logo
ATRC
AtriCure
1.3$58.16-0.2%$2.62 billion$230.81 million-50.57
Integer logo
ITGR
Integer
2.3$77.74-0.5%$2.57 billion$1.26 billion35.34
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$47.17-1.4%$1.87 billion$236.54 million-71.47
Alphatec logo
ATEC
Alphatec
0.8$14.55-2.5%$1.17 billion$113.43 million-13.23
CryoLife logo
CRY
CryoLife
1.5$25.09-0.5%$969.87 million$276.22 million-66.02
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$44.56-0.9%$868.77 million$459.95 million37.13
AngioDynamics logo
ANGO
AngioDynamics
1.6$18.91-1.9%$704.04 million$264.16 million-4.23
Surmodics logo
SRDX
Surmodics
1.5$46.89-1.2%$633.89 million$94.86 million586.13News Coverage
Accuray logo
ARAY
Accuray
2.2$5.06-0.4%$463.67 million$382.93 million36.14Upcoming Earnings
Invacare logo
IVC
Invacare
1.6$9.77-1.5%$341.43 million$927.96 million-7.94
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.41-3.9%$136.62 million$61.30 million-3.27
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.